LONDON, April 24 (Reuters) - Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk (NOVOb.CO), opens new tab has raised its annual sales guidance several times a year.

STORY: Since launching its popular weight-loss drug Wegovy in 2021, Novo Nordisk has raised its annual sales guidance several times a year. But recent weak U.S. prescription data is leading some ...

LONDON (Reuters) - Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk has raised its annual sales guidance several times a year. But recent weak U.S. prescription ...

LONDON (Reuters) - Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk has raised its annual sales guidance several times a year. But recent weak U.S. prescription data is ...

People who’ve been using more affordable copycat versions of Ozempic or Wegovy to lose weight will no longer have that option. “They are generally much more accessible — you can get them ...

The United States Food and Drug Administration (FDA) has stopped the sale of copycat versions of Ozempic and Wegovy, the Type 2 diabetes drugs used for weight loss. In 2022, the FDA announced ...

Ozempic (semaglutide) and Wegovy (semaglutide) are prescription drugs that may be used to help with long-term weight loss. But only Wegovy is FDA approved for this use. Both drugs are approved for ...

A daily pill appears to lower blood sugar in people with type 2 diabetes as effectively as injectable drugs like Ozempic and Mounjaro. The medication, called orforglipron, also led to substantial ...